ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

IMAB I MAB

1.84
-0.02 (-1.08%)
14 Jun 2024 - Closed
Delayed by 15 minutes
Name Symbol Market Type
I MAB NASDAQ:IMAB NASDAQ Depository Receipt
  Price Change % Change Price Bid Price Offer Price High Price Low Price Open Price Traded Last Trade
  -0.02 -1.08% 1.84 1.66 3.73 1.86 1.83 1.85 98,437 21:25:00

I-Mab to Report Mid-Year 2023 Financial Results, Business and Corporate Updates on August 17, 2023

08/08/2023 1:00pm

PR Newswire (US)


I MAB (NASDAQ:IMAB)
Historical Stock Chart


From Jun 2023 to Jun 2024

Click Here for more I MAB Charts.

ROCKVILLE, Md. and SHANGHAI, Aug. 8, 2023 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of pioneering immunotherapies, today announced that it will report business and corporate updates and financial results for the six months ended June 30, 2023, before the market opens on Thursday, August 17, 2023, and host a conference call to discuss the results and provide corporate updates at 8:00 a.m. EST.

I-MAB Logo (PRNewsfoto/I-Mab Biopharma)

I-Mab Conference Call Information

Investors and analysts are invited to join the conference call at 8:00 a.m. EST on August 17 via Zoom:

Link: https://i-mabbiopharma.zoom.us/j/87349766033?pwd=bFhVejFDS1dHeWw3eklaeW1JcFhpUT09 

Meeting ID: 873 4976 6033

Password: 194422

About I-Mab

I-Mab (Nasdaq: IMAB) is a global biopharmaceutical company exclusively focused on bringing transformational medicines to patients around the world through the discovery, development, and potential commercialization of novel or highly differentiated immunotherapies and biologics for oncology. I-Mab's innovative pipeline, including five key clinical assets and a pipeline of early-stage clinical and pre-clinical stage drug candidates are driven by the internal R&D's Fast-to-Proof-of-Concept and Fast-to-Market development strategies and through global partnerships. For more information, please visit http://www.i-mabbiopharma.com and follow us on LinkedIn, Twitter, and WeChat.

I-Mab Contacts


Investors


Media

Richard Yeh

Chief Operating Officer, interim Chief Financial Officer

IR@i-mabbiopharma.com

Gigi Feng

Chief Communications Officer

PR@i-mabbiopharma.com

 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/i-mab-to-report-mid-year-2023-financial-results-business-and-corporate-updates-on-august-17-2023-301895502.html

SOURCE I-Mab

Copyright 2023 PR Newswire

1 Year I MAB Chart

1 Year I MAB Chart

1 Month I MAB Chart

1 Month I MAB Chart

Your Recent History

Delayed Upgrade Clock